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Abstract
Oligomeric proanthocyanidins extracted from the
bark of the French maritime pine Pinus pinaster
(FMPBE) have been studied for a long time and
demonstrated various phytopharmaceutical appli-
cations. The objectives of this study were to assess
the cutaneous lightening and anti-ageing effects of
FMPBE after 56 days of consumption, in healthy
Asian women. The cosmetic efficacy of the product
was assessed through various biometrological eval-
uations. This randomized, double-blind, placebo-
controlled and cross-over study evidenced the safety
and efficacy of the 100 mg FMPBE supplementation
from 28 days of intake: in comparison to placebo,
the skin on pigmentary spots became significantly
lighter and less red, skin on the face was more firm
and its surface was less wrinkled. After 56 days of
consumption, the skin was additionally significantly
more elastic and the yellow constituent of the skin
decreased on the normal skin. 
Taken together, these results proved that FMPBE
supplementation can be considered as an innova-
tive approach to skin whitening and anti-ageing
treatments. It represents an interesting alternative
to topical products and supports the skin from the
inside out.
Introduction
Polyphenols are a wide range of biological molecules
which play a protective role in plants. They are one
of the major types of secondary metabolites and
include several types of molecules, such as phenolic
acids and flavonoids. Oligomeric ProanthoCyani-
dins (OPC) — also designated as procyanidins, leu-
coanthocyanidins or condensed tannins — are
oligomeric flavonoids. OPCs are very common in
all plants and are found in many foods (fruits, veg-
etables, chocolate, cider, wine and tea among oth-
ers). Historically, their well known property was to
complex proteins, which explains their astringent
taste and their use in tanning. Further work, mainly
by Masquelier in France, showed their veinotonic
properties and vitamin C2 activity (allowing better
intake and use of vitamin C by the body) [1, 2].
Later, thanks to their strong antioxidant properties,
more studies were carried out on OPCs in the nu-
trition and preventive medicine area [3].
OPCs extracted from the bark of the French maritime
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bark extract after 56 days of consumption in healthy
women. The cosmetic efficacy of the product was
assessed through various biometrological evaluations. 
A randomised, double-blind, placebo-controlled,
cross-over design was employed for this study. It
took place at Dermscan Asia (Bangkok, Thailand).
The study was conducted in compliance with Good
Clinical Practices.
Subjects
The minimum planned number of subjects to be
analysed was 30. In order to participate in the study,
women had to over 45 years old and Asian with
phototype IV or V. They had to present slight wrin-
kles or fine lines on crow’s feet and at least two
pigmentation spots on face and/or hands and/or
cleavage. The consumption of food supplements
in the two previous months or during the study
was forbidden. Subjects with an unbalanced weight
or using any topical or systemic treatment likely
to interfere with the assessment of the efficacy eval-
uation were excluded. Intensive exposure to sun-
light or UV rays within the previous month or fore-
seen during the study were not accepted. Subject’s
participation in the study came into effect only af-
ter providing full informed consent. All procedures
followed were in accordance with the ethical stan-
dards of the responsible committee on human ex-
perimentation (institutional and national) and with
the Helsinki Declaration of 1975, as revised in 2000.
Products
Each active capsule contained (% by weight) 50
mg of pine bark extract (17.9%) (manufactured by
DRT company, Purextract department, sold under
the trade names Oligopin® and Cosmythic®), 200
mg maltodextrin (71.4%) and 30 mg magnesium
stearate (10.7%). 
The active ingredient used in this study is a purified
extract from FMPB (P. pinaster, Aiton). It is obvious
that, according to the extraction process used, one
can obtain many finished products, even when us-
ing the same raw material, leading to differing
pine Pinus pinaster have been studied for a long time
(for review, see [4, 5]). In vitro, French maritime pine
bark extract (FMPBE) showed good antioxidant
power, especially in the human low-density lipopro-
tein model [6]. A study evaluated the effect of long-
term supplementation with FMPBE on rats and Syr-
ian hamsters, especially on plasma antioxidant
activity and atherosclerosis prevention [7]. FMPBE
showed no toxicity and no side effects during the
period of experimentation. Also, it did not have any
influence on daily intake. FMPBE was absorbed and
induced measurable biological activity. FMPBE im-
proved the resistance of the heart against free radical
oxidation. OPCs were more active and most probably
more bioavailable than high-molecular-weight tan-
nins and had an effective and strong protective anti-
oxygen free radical activity. There was a significant
reduction of oxidized lipids at the surface of the ar-
teries (atherosclerotic arteries) in the group supple-
mented with FMPBE. FMPBE also prevents chronic
UVB radiation-induced skin damage and carcino-
genesis in melanin-possessing hairless mice [8].
A clinical study assessed the effect of a daily dosage
of 80 mg of FMPBE on melasma (40 mg twice a
day) [9]. The results clearly showed an improvement
both on skin lightening and melasma reduction af-
ter one month. In 2005, another clinical study
showed good results in the evaluation of the effect
of a blend of ingredients including FMPBE on skin
beauty (mainly anti-wrinkle and skin elasticity) [10].
FMPBE, as shown by in vitro and in vivo testing and
clinical studies, has been used in health and beauty
food supplements and functional food products,
providing interesting biological effects, without
side effects [5]. The aim of this study was to pre-
cisely quantify the effect of FMPBE on skin beauty:




The objectives of this study were to assess the cuta-




inclusion and non-inclusion criteria, one zone on
the back and two zones on subjects’ spots (either
on face, hands or cleavage) were defined. The per-
son in charge of the medical exam and of the se-
lection of the spots checked with the subjects that
they were not some nevus or any other birthmark,
to select only lentigo senile. Measurements of skin
colour with a Minolta CM700d spectrophotometer
were performed on the three defined areas. A skin-
print was performed on one defined crow’s foot in
order to evaluate skin relief parameters using a Skin
Image Analyser® (SIA®) and QuantiRides® software.
Biomechanical cutaneous properties on the defined
crow’s foot were measured with a Cutometer®. A
macrophotograph of each pigmentary spot was
taken and the first treatment (active or placebo)
was distributed to the subjects according to the
randomisation list. Women had to take one capsule
in the morning and one in the evening. A daily
log was also provided in order to register any con-
comitant treatment or adverse events.
Day 28: the subjects came back to the laboratory
with their treatment and completed a daily log.
The same measurements were performed as on D0,
on the same zones. The product was distributed
again to the subjects as well as a new daily log.
Day 56: The subjects came back to the laboratory
with their products and completed a daily log. The
same measurements were performed as on D0, on
the same zones. 
After a wash-out period of 14 days, during which
the subjects did not have to take any test products,
the women came back for the second period of trial.
Period 2
Day 0: The same measurements were performed as
the ones in Period 1 on D0, on the same zones
(skin colour on back and pigmentary spots, bio-
mechanical cutaneous properties and skinprint in
crow’s foot, macrophotographs on pigmentary
spots). The second treatment (active or placebo)
was distributed to the subjects according to the
randomisation list. Women had to take one capsule
chemical composition and biological activity [11].
Chemical composition of the present product has
been established using different analytical tech-
niques, including HPLC, gel permeation chromatog-
raphy, mass spectrometry, NMR and chemical tests
(Bate-Smith, Folin, vanillin test). According to these
different methods, the composition of the product
was defined (Table 1).
Each placebo capsule contained (% by weight) 250
mg maltodextrin (89.3%) and 30 mg magnesium
stearate (10.7%). These capsules were identical in
shape, smell, taste and weight to the active capsules.
The dosage of 100 mg/day of FMPBE tested in this
study corresponded to less than 1/500th of the no
observed adverse effect limit (NOAEL). This selected
dosage (100 mg/day) was in accordance with some
previous clinical studies: one clinical study demon-
strated the effect of FMPBE at 80 mg/day [12] for
melasma treatment. Furumura et al. [13] used it at




Day 0: After a medical exam in order to check the
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Table 1 Chemical composition of FMPBE used in this study
Compound Content (average, mass %)
Procyanidolic oligomers*, including 65–75
Dimers 15–20
Trimers 15–20











*Procyanidolic oligomers: low-molecular-weight polymers (dimer to hexamer) of
catechine and epicatechine (sometimes referred to as low-molecular-weight con-
densed tannins).
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These shadows are observed with a digital camera
linked to a computer. A 1 cm² area is studied. The
digitised picture obtained is analysed in grey levels
and allows assessment of different parameters of the
skin surface relief. The parameters studied with the
QuantiRides® software (Monaderm, Monaco) are the
total wrinkled surface (in mm²), and the number
and the average depth (in μm) of cutaneous mi-
crorelief furrows (depth <55 μm), medium wrinkles
(55–110 μm depth) and deep wrinkles (depth >110
μm). A decrease in the microrelief furrows charac-
terises a smoothing effect. Decreases in the medium
or deep wrinkles and of the total wrinkled surface
characterise an anti-wrinkle effect.
SEM 575 Cutometer® (Courage & Khazaka)
The skin is sucked into the orifice of a probe by
constant vacuum pressure (300 mbar) for 3 s fol-
lowed by a 2-s relaxation period. The depth to
which the skin penetrates into the probe is meas-
ured by two optical prisms located at the opening
of the probe’s orifice. These measurements define
different parameters characterising the biomechan-
ical properties of tegument:
• Firmness (parameter R0): A decrease of this pa-
rameter means firmer skin
• Elasticity (parameters R2, R5 or R7): An increase
of one of these parameters indicates more elastic
skin. Parameter R6 is also representative of the
state of skin elasticity: its decrease characterises
more elastic skin. 
• Fatigability (parameter R9): A decrease of this pa-
rameter indicates an improvement of the cuta-
neous state.
Macrophotography
The digital camera used was a Nikon D100 or D70.
The photographs were taken in standardised, indi-
rect light. Aperture, speed and distance of the cam-
era were also standardised. The control of the repo-
sitioning took place directly on a data-processing
screen thanks to simultaneous visualisation of the
images at various times of acquisition.
in the morning and one in the evening. A daily
log was also provided in order to register any con-
comitant treatment or adverse events.
On D28 and D56, the subjects came back to the
laboratory with their treatment and completed
daily log. The same measurements as on D0 in Pe-
riod 1 were performed, on the same zones. 
Evaluation tools
CM700d spectrophotometer (Minolta)
Skin colorimetric measurements were performed
with apparatus equipped with a 3 mm diameter
head. The device converts colours perceived by hu-
mans to a digital code composed of three parame-
ters: L* (for clarity from dark to light), a* (for the
green-to-red spectrum) and b* (for the blue-to-yel-
low spectrum). a* and b* are chrominance parame-
ters and L* is a luminance parameter. It is therefore
possible to express the differences between two cu-
taneous zones that appear to be the same colour in
minute detail. After a calibration phase, measure-
ments are made directly on the skin using a pulsed
xenon light source and a dual beam system designed
to measure the light transmitted and to correct any
slight deviation. This instrument is commonly used
in cosmetics and medicine to measure skin colour.
The parameters L* (luminance) and b* (cutaneous
melanin yellow colour) are studied during a light-
ening product study. Both parameters are exploited
through the calculation of the individual typologi-
cal angle, which defines the skin pigmentation de-
gree of a subject according to the following formula:
ITA°=[Arc tan((L*–50)/b*)]×180/π. The higher the
ITA° is, the lighter the skin is. For pigmentary spots,
the a* parameter is also interesting to study because
the “red” component is important in spots.
SIA®
Polymer silicon skinprints (Silflo®) were taken of the
studied zones, before product use and at each time
of measurement, then studied using a Skin Image
Analyser® (SIA®). For that purpose, an oblique light-




spectively), reflecting a significant lightening effect
of the skin and a decrease of the cutaneous pigmen-
tation on the back. The b* parameter also signifi-
cantly decreased after 56 days of intake (p=0.0145),
meaning that the yellow constituent of the skin was
reduced. No significant modification of any of these
parameters was observed after 56 days of placebo
consumption.
When comparing the two treatments on D56, the
FMPBE significantly decreased the yellow con-
stituent of the skin (b* parameter) compared to
placebo (p= 0.097).
Skin colour evaluation on pigmentary spots see
Table 3)
Already after 28 days of FMPBE intake, L* and ITA°
parameters were significantly increased and a* was
significantly decreased reflecting a significant light-
ening effect of the skin and a decrease of the red cu-
taneous pigmentation on spots. Regarding placebo
consumption, skin appeared significantly more red
on spots after 56 days of intake (a* parameter;
p=0.047).
Statistics
For each studied parameter (spectrophotometer and
Cutometer® measurements, wrinkle analysis) and for
each product, the descriptive statistics for quantitative
variables of the original data (before and after 28 days
and 56 days of product use) and of the changes from
baseline (Dx–D0) were computed and tabulated. 
A mixed ANOVA model was fitted to the change
outcome (Di–D0). The factors taken into account
were product effect (as fixed with two levels), period
effect (as fixed with two levels, D0 to D56 and D70
to D126), sequence effect (as fixed with two levels,
product/placebo and placebo/product) and subject
nested within sequence (as random effect). The LS-
means statement will be used to (i) assess the
change on Di from baseline (D0) within each group
of product and (ii) test whether the products differ
significantly between them.
The underlying assumptions (homoscedasticity and
residual normality) were checked with graphs and
the Shapiro-Wilk test (α=0.01). In case of strong
deviation, an equivalent non-parametric approach
was applied. Each categorical response of the sub-
jective questionnaire was described and tabulated
by frequency and percentage (N, %) at each evalu-
ation time. No comparative analysis between prod-
ucts was performed. The type I error was set at 10%
in a two-tailed approach and the Microsoft® Excel
and SAS® 9.2 software programs were used.
Results
Thirty-five women were included in the study but
one subject did not come for the visit on D28 and
was therefore dropped from the study. Thirty-four
women, with a mean age of 60±1 years (46–70
years), completed the study. Both treatments were
very well tolerated, with no declared adverse effects
after 56 days of intake.
Skin colour evaluation on normal skin (back) 
(see Table 2)
After 56 days of FMPBE intake, L* and ITA° parame-
ters significantly increased (p=0.076 and p=0.016 re-
Nutrafoods (2014) 13:123-131
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Table 2 Skin colour estimate changes (mean Δ%) on the back
and comparison of products: analysis of the ITA°, 
L* and b* parameters
Parameter Change Product Mean Δ% p-value
ITA° (D28–D0) FMPBE 1 0.058
Placebo 1 0.032
FMPBE vs. placebo 0.838
(D56–D0) FMPBE 7 0.016
Placebo 2 0.203
FMPBE vs. placebo 0.355
L* (D28–D0) FMPBE 0 0.250
Placebo 0 0.129
FMPBE vs. placebo 0.782
(D56–D0) FMPBE 1 0.076
Placebo 0 0.216
FMPBE vs. placebo 0.653
b* (D28–D0) FMPBE –1 0.113
Placebo 0 0.518
FMPBE vs. placebo 0.493
(D56–D0) FMPBE –1 0.015
Placebo 0 0.928
FMPBE vs. placebo 0.097
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• A significant decrease in the depth of deep wrin-
kles after 28 and 56 days of product intake of
respectively –7% (p=0.081) and –8% (p=0.085)
on average. 
These results characterise an anti-wrinkle effect of
FMPBE after 28 days of intake. The anti-wrinkle ef-
fect was measured in approximately 65%–71% of
the subjects.
Fifty-six days of placebo consumption induced a
significant reduction of –2% on average in the depth
of microrelief furrows (p=0.087), meaning smoother
skin, without anti-wrinkle effect. This smoothing
activity was observed on 62% of the subjects.
Evaluation of cutaneous biomechanical
properties on the temple (data not shown)
After 28 days and 56 days of FMPBE intake and in
comparison with the initial state:
• Skin firmness was significantly increased (mean
variations of –8% after 28 days, p<0.001; and 
–7% after 56 days, p<0.001). The improvement
of skin firmness was statistically different from
the placebo group (p=0.014 on D28 and p=0.014
on D56).
• Skin elasticity was significantly improved on
D56 (mean variations of +3%, p=0.057 for R2
parameter and +4%, p=0.066 for R7 parameter).
• Skin fatigability was significantly decreased
(mean variations of –9% after 28 days, p=0.002
and –9% after 56 days, p=0.028). The reduction
of skin fatigability was statistically different from
the placebo group on D28 (p=0.028).
No significant variation of rheological characteris-
tics of the skin was registered with the placebo
treatment.
Macrophotographies
An example of results obtained with FMPBE on
pigmentary spots is presented in Fig. 1.
Discussion
Within Asia, the population 65 years and older is
expected to grow dramatically over the next 50
After 28 days of treatment with the FMPBE and
compared to the placebo, the skin was significantly
lighter (ITA° and L* parameters) and less red (a*) on
pigmentary spots. It stayed significantly lighter (ITA°
parameter) and less red (a*) after 56 days of intake.
Wrinkle evaluation on crow’s foot skinprint 
(see Table 4)
Under these study conditions, FMPBE induced the
following:
• A significant decrease in the total wrinkled sur-
face of –15% on average (p=0.026) after 28 days
of product intake. This effect was significantly
different from the placebo effect (p=0.003) after
28 days and less significantly different after 56
days (p=0.108).
• A significant decrease in the number of medium
wrinkles of –12% on average (p=0.075) after 28
days of product intake. 
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Table 3 Skin color estimate changes (mean Δ%) on the back,
on each Di from baseline (D0) and comparison of
products: analysis of the parameters ITA°, L*, b* and a*
Parameter Change Product Mean Δ% p-value
ITA° (D28–D0) FMPBE 6 0.004
Placebo 2 0.349
FMPBE vs. placebo 0.093
(D56–D0) FMPBE 12 0.000
Placebo 4 0.165
FMPBE vs. placebo 0.062
L* (D28–D0) FMPBE 0 0.001
Placebo 0 0.220
FMPBE vs. placebo 0.068
(D56–D0) FMPBE 1 0.000
Placebo 0 0.056
FMPBE vs. placebo 0.134
b* (D28–D0) FMPBE 0 0.670
Placebo 0 0.758
FMPBE vs. placebo 0.942
(D56–D0) FMPBE –1 0.344
Placebo 0 0.931
FMPBE vs. placebo 0.464
a* (D28–D0) FMPBE -2 0.020
Placebo 1 0.508
FMPBE vs. placebo 0.039
(D56–D0) FMPBE –2 0.017
Placebo 1 0.047
FMPBE vs. placebo 0.004
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oldest age group. As people live longer, there is a
growing demand for both healthcare and skincare.
Many people seek cosmetic procedures to enhance
or preserve their facial features in order to maintain
a youthful appearance.
years. As a whole, this age group is expected to
grow by 314% in Asia: going from 207 million in
2000 to 857 million by 2050 [16]. In most Asian
countries, similar to the rest of the world, older
women outnumber older men, particularly in the
Nutrafoods (2014) 13:123-131
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Table 4 Skin relief estimate changes (mean Δ%) on the crow’s foot, on each Di from baseline (D0) and comparison of products.
Parameters with no significant change are not presented here
Parameter Change Product Mean Δ% p-value
Depth of microrelief furrows (µm) (D28–D0) FMPBE 0 0.636
Placebo 0 0.782
FMPBE vs. placebo 0.876
(D56–D0) FMPBE 0 0.71
Placebo –2 0.087
FMPBE vs. placebo 0.173
Number of medium wrinkles (D28–D0) FMPBE –12 0.075
Placebo –8 0.185
FMPBE vs. placebo 0.741
(D56–D0) FMPBE 0 0.906
Placebo –1 0.904
FMPBE vs. placebo 0.998
Depth of medium wrinkles (µm) (D28–D0) FMPBE 2 0.037
Placebo 3 0.001
FMPBE vs. placebo 0.300
(D56–D0) FMPBE 1 0.455
Placebo 1 0.341
FMPBE vs. placebo 0.882
Depth of deep wrinkles (µm) (D28–D0) FMPBE –7 0.081
Placebo 1 0.880
FMPBE vs. placebo 0.193
(D56–D0) FMPBE –8 0.085
Placebo 0 0.967
FMPBE vs. placebo 0.292
Total wrinkled surface (mm²) (D28–D0) FMPBE –15 0.026
Placebo 13 0.135
FMPBE vs. placebo 0.003
(D56–D0) FMPBE –9 0.197
Placebo 10 0.275
FMPBE vs. placebo 0.108




order to assess the skin lightening and anti-ageing
effects of FMPBE after 56 days of consumption, in
healthy women. This randomised, double-blind,
placebo-controlled, cross-over study evidenced the
efficacy of 100 mg FMPBE supplementation from
28 days of intake: in comparison to placebo, the
skin on pigmentary spots became significantly
lighter and less red, skin on the face was more firm
and its surface was less wrinkled. After 56 days of
consumption, the skin was additionally signifi-
cantly more elastic and the yellow constituent of
the skin was decreased on the normal skin.
In this study, the levels of efficacy obtained thanks
to oral supplementation were comparable to or bet-
ter than the results that could be achieved with top-
ical application. Furthermore, significant changes
appeared already after 28 days of consumption, cor-
responding to rapid action. The cutaneous changes
obtained in the presence of FMPBE could be the re-
sult of combined activities: it traps lipid peroxides
and free radicals, and it also chelates to free iron
molecules, so as to inhibit iron-induced lipid per-
oxidation; it non-competitively inhibits xanthine
oxidase, a major generator of free radicals [3, 18].
FMPBE prevents the release of pro-inflammatory
mediators regulated by oxidative stress [14, 15, 19].
As UV radiation is a major source of reactive oxygen
species leading to oxidative stress, inflammation and
pigmentary disorders, FMPBE is indicated to coun-
teract UV-induced damage. The lightening effect ob-
tained in this study on both pigmentary spots and
normal skin is in accordance with previous obser-
vations on photoaged facial skin in the presence of
a FMPBE supplementation [13] or UV-induced skin
damage [14]. It was shown in vitro that OPCs from
either FMPBE or grapeseed influence the NF-κB sig-
nalling pathway activated by UV-induced oxidative
stress [14, 20]. The firming and anti-wrinkle effects
measured from 28 days of supplementation should
be linked to FMPBE anti-inflammatory properties
and its capacity of inhibition of enzymes degrading
connective tissue structures (hyaluronidase, elastase,
collagenase, gelatinase) [21, 22]. It could be also
The cutaneous ageing of the face is characterized,
on an aesthetic level, by cumulative phenomena
including cutaneous relaxation, volume reduction
(notably at the cheekbones and mouth levels), the
presence of wrinkles and furrows, and colour het-
erogeneity. These ageing manifestations are the re-
sult of the combined effects of gravity, decreased
tissue elasticity, progressive bone resorption and
subcutaneous fat redistribution. Pigmentary and
vascular impairments are responsible for colour
heterogeneity. The rate of ageing can be signifi-
cantly different among different populations. In-
trinsic ageing is a natural process and is genetically
determined. In Asia, brown spots, clinically diag-
nosed as solar lentigines, are the first visible sign
of ageing [17], whereas wrinkles represent the first
cutaneous marks of the passing years in Europe.
Cosmetic products are the most popular and most
used anti-ageing treatments. They have become in-
creasingly high-tech, acting very specifically on cel-
lular phenomena responsible for cutaneous ageing.
Topical anti-wrinkle actives have several targets: (i)
at the epidermal level, they modulate keratinocyte
differentiation and stimulate keratinocyte renewal;
(ii) at the dermal level, they slow down dermal
components’ degradation and stimulate their syn-
thesis. They also favour fibroblast renewal and wa-
ter retention and maintain fundamental theme vol-
ume. Some of the well known actives used are
retinol, vitamin C, hyaluronic acid and α-hydroxy
acids. Whitening care products, leading to an over-
all skin lightening effect, were first aimed at Asian
women. Nowadays, Western markets are also in-
terested in these products, combating localised hy-
perpigmentation and dull complexion. Most
whitening agents use inhibitors of tyrosinase, a key
enzyme in melanogenesis, or the activity of its me-
diators. Topical products designed today for skin
lightening mainly employ arbutin, kojic acid or
azelaic acid. These ingredients are often associated
with antioxidants, agents promoting desquamation
and sunscreens. 
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linked to the enhancing action of pine OPCs on vi-
tamin C catalyst synthesis of collagen [2]. 
Taken together, these results proved that FMPBE
supplementation can be considered as an innovative
approach to skin whitening and anti-ageing treat-
ments. Effective skin bleaching, firming and anti-
wrinkle effects can be obtained already after 28 days
of 100 mg intake per day, with a high level of safety.
It represents an interesting alternative to topical
products and supports the skin from the inside out.
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